FDA clears Boehringer's Gilotrif for metastatic lung cancer

07/15/2013 | PharmaTimes (U.K.) · Reuters

Boehringer Ingelheim obtained the FDA's approval to market Gilotrif, or afatinib, for treatment of patients with metastatic nonsmall-cell lung cancer whose tumors show certain epidermal growth factor receptor mutations. The approval was based on data from a 345-patient trial.

View Full Article in:

PharmaTimes (U.K.) · Reuters

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Fort Worth, TX
Director, Senior Legal Counsel
Fort Worth, TX